Form 8-K - Current report:
SEC Accession No. 0001753926-24-002052
Filing Date
2024-12-10
Accepted
2024-12-10 09:29:44
Documents
16
Period of Report
2024-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084587_8k.htm   iXBRL 8-K 45828
2 EXHIBIT 10.1 g084587_ex10-1.htm EX-10.1 136493
3 EXHIBIT 10.2 g084587_ex10-2.htm EX-10.2 57834
4 EXHIBIT 10.3 g084587_ex10-3.htm EX-10.3 17791
  Complete submission text file 0001753926-24-002052.txt   483878

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lipo-20241205.xsd EX-101.SCH 3012
6 XBRL LABEL FILE lipo-20241205_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE lipo-20241205_pre.xml EX-101.PRE 22357
18 EXTRACTED XBRL INSTANCE DOCUMENT g084587_8k_htm.xml XML 3813
Mailing Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208
Business Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208 412-901-0315
LIPELLA PHARMACEUTICALS INC. (Filer) CIK: 0001347242 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41575 | Film No.: 241537304
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)